July 1, 2011


Eli Lilly's government lobbying costs rise in Q1



Eli Lilly and Co. spent US$2.5 million in the first quarter lobbying the US federal government on access to foreign markets, tax issues, and a host of other topics.


The Indianapolis-based pharmaceutical company raised its spending 8% from the US$2.3 million that it spent in the first quarter of last year. It also spent 70% more than the US$1.5 million recorded in the final quarter of 2010, according to lobbying reports filed with the House of Representatives.


Eli Lilly has cited its animal health business as an important source for future growth as it seeks to replace the revenue lost when sales of its key products fall due to the expiry of its patents later this year, which would allow generic competition to enter the market.


Besides Congress, Eli Lilly also lobbied the Patent and Trademark Office, the US Trade Representative, the Food and Drug Administration, the Office of Management and Budget, and the departments of Commerce, State, Agriculture, and Homeland Security.

Video >

Follow Us